Monday, 20 July 2020

Digital 3D Printing Market 2019 – Leading Manufactures, Regions, Drivers, Analysis And Forecasts Till 2025

Digital 3D Printing Market size is expected to register a CAGR of 20.54% to reach USD 5,214.8 Million by 2025. 3D Printing is a process in which physical objects are created by depositing materials in layers based on a digital model. The creation of a 3D printed object is achieved using additive processes. In an additive process, an object is created by laying down successive layers of materials until the object is created. 3D Printing enables to produce complex shapes using less material than traditional manufacturing methods. Each 3D Printing process requires software, hardware, and materials to work together.
Market Dynamics
Increasing applications of Digital 3D Printing in healthcare industry is expected to boost market growth. 3D Printing techniques have empowered medical practitioners, manufacturers of medical devices, as well as researchers due to their use in dental & orthodontic treatments, orthopedic implants, tissue engineering, and drug development. As a result, the increasing benefits of the mentioned applications would boost digital 3d printing market growth. 3D Printing technique is useful to speed up procedures and helps to minimize the trauma faced by patients due to conventional treatment options. Technological advancements in digital 3D Printing, rising public-private funding for 3D Printing activities are the major drivers that contribute to the growth of the digital 3D Printing market.
Segmentation
Global Digital 3D Printing Market analysis is segmented based on Component, Material, Technology, Application and End User.
The market, based on component, has been categorized as system/device and software/services. System/Device held 867.53 market value in 2018
Global digital 3D Printing market, based on material, has been segregated into polymers, metal & alloy, ceramics, and others.
Global digital 3D Printing market trends based on technology, has been segregated into stereolithography, deposition modeling, laser sintering, jetting technology, electron beam melting, and others.
Global digital 3D Printing market based on application has been categorized into dental, prosthetics, orthopedics, medical components, tissue engineering, hearing aids, drug screening, and others.
Global digital 3D Printing market, based on end user, has been segregated into hospitals & surgical centers, dental clinics & laboratories (offices), pharmaceutical & biotechnology companies, and others.
Regional Analysis
Global Digital 3D Printing Market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas led the market and accounted for the largest share in 2018, owing to the existence of medical device companies and the rising prevalence of diseases along with increased adoption of treatment by patients. In North America, the US held the largest of the market share in 2018 owing to the presence of major market players, developed healthcare infrastructure, high awareness, and availability of advanced treatment options. For instance, in November 2015, a group of medical researchers from North Carolina’s Wake Forest University developed a method to print the 3D form of custom medications in the configuration of pills. As a result, increasing applications of 3D Printing is expected to drive the market growth.
Europe accounts for the second-largest share in the global digital 3D Printing market owing to the presence of favorable government initiatives & laws and target population base, rising prevalence of lifestyle-associated conditions, and the presence of developed economies such as Germany, the UK, and France. Since the ban on animal testing for cosmetics in 2013, the wellness industry had been a significant supporter of 3D Printing in Europe.
Asia-Pacific is estimated to be the fastest-growing market during the forecast period due to the increasing per capita health spending, growing older population base, rising incidence of accidents, and developing the healthcare sector in China, Japan, India, and Australia.
The Middle East & Africa digital 3D Printing market is segmented into two major regions, namely the Middle East and Africa. In this region, the Middle East is anticipated to dominate owing to the presence of countries such as Egypt, Saudi Arabia, and others. The Middle East and Africa has less economic developments and extremely low-income due to which the region accounts for the least market share but is expected to grow with the increasing cases of chronic diseases and demand for better treatments in countries.
Key Players
The Prominent Players in the Global Digital 3D Printing Market are Stratasys Ltd (US), 3D Systems, Inc. (US), Carbon, Inc. (US), EnvisionTEC (US), Formlabs (US), ExOne (US), Materialise (Europe), General Electric (US), Micron Dental (US), Renishaw PLC (UK).
Some of the key strategies followed by players operating in the Global Digital 3D Printing Market were acquisitions, expansions, product launches, partnerships, mergers, collaborations, alliances, and product approvals.
  • In June 2019, Materialise received the FDA clearance for the cardiovascular planning software suite. Thus, the suite has helped clinicians to produce patient-specific 3D models for more than 20 years.
  • In November 2019, ExOne introduced the X1 160PRO metal 3D printer for high-volume production of quality parts.
  • In February 2019, EnvisionTEC and AvaDent digital dental solutions announced a new partnership. This partnership offered a complete digital workflow solution for digital dentures, from impressions and digital design to try-in and final restoration.
                                                                                                                     
Posted by at No comments:

Global Hyperspectral Imaging System Market Outlook, Key Financials, Segmental Revenue And Geographical Revenue Till 2025

Global Hyperspectral Imaging System Market held a value of USD 10,700 Million in 2018, at a CAGR of 17.4% during the assessment period of 2019 to 2025.
Hyperspectral Imaging System Market Synopsis
Hyperspectral Imaging Systems (HIS) are also known as imaging spectroscopy. It was originated from remote sensing and has various applications in surveillance, remote sensing, machine vision/optical, and medical diagnostics. It can acquire 2D images across a wide range of the electromagnetic spectrum. Increasing applications for research in life sciences and the medical diagnostics sector in the past few years are responsible for a surge in demand for hyperspectral imaging systems. The key players involved in this market are actively focusing upon building partnerships, collaborations, and joint ventures with hospitals and ambulatory centers to strengthen their position in the market. Moreover, there is an increasing growth in various chronic diseases, which pushes the need for efficient hyperspectral imaging systems in the developing as well as underdeveloped regions.
Hyperspectral Imaging System Market Influencer
Rising funding and investments for the development of hyperspectral medical imaging systems are likely to provide favorable conditions for the growth of the hyperspectral medical imaging system market during the forecast period.
Hyperspectral Imaging System Market Drivers
  • The growing industrial applications of hyperspectral imaging is anticipated to drive the growth of the market during the forecast period. It has various applications in food & agriculture, healthcare, defense, mining, and metrology industries.
  • Innovative and easy to use product launched in recent years
  • Rising spending on scientific research and aerospace industry
  • The growing prevalence of cancer and increasing awareness of innovative diagnostics methods is providing favorable conditions for the growth of the market during the forecast period. According to the US Department of Health and Human Services, 1,735,350 new cases of cancer were detected in the US in 2018. It is expected to accelerate the demand for hyperspectral imaging systems during the study period
  • High investment in research and development for the development of efficient imaging solutions
Market Restraints
  • High costs associated with HIS are likely to hamper the market growth
  • Data storage-related issues associated with HIS
Hyperspectral Imaging System Market Segmentation

By Product
  • Visible/Near-Infrared (VNIR): These systems create a false-color composite image made using near-infrared, green, and blue wavelengths. They are used in healthcare and agriculture sectors. VNIR segment is estimated to hold the largest market share during the forecast period due to the ease in operating and high efficiency of VNIR products
  • Mid-Wave Infrared (MWIR): Mid-Wave Infrared (MWIR) systems operate in wavelengths ranging from 3µm to 5µm (3000nm to 5000nm). This segment is anticipated to be the fastest-growing segment owing to the rising adoption of MWIR systems in detecting volcanic vents, industrial gas leaks, or biomass burning events.
  • Short-Wave Infrared (SWIR): It operates in wavelengths between 1,050 and 2,500 nm and used in inspection, sorting, and quality control. It has various applications including surveillance and remote sensing.
  • Long-Wave Infrared (LWIR): Long-Wave Infrared (LWIR) systems are used in the detection of minerals such as quartz, adularia, albite, kaolinite, orthoclase, Na- and Ca-montmorillonite, calcite, opal, chalcedony, gypsum, alunite, jarosite, and other sulfates.
By Technology
  • Pushbroom: These devices are made up of digital micromirror devices (DMD), CMOS image sensors. It is also called a line scan. This segment is estimated to hold maximum market share during the forecast period. The growth of this segment is attributed to the growing popularity of push broom systems in computer vision, remote sensing, biomedicine, surveillance, precision agriculture, environmental studies, forensics, nanoparticle research, food science, mining, forestry, etc.
  • Snapshot: Snapshot hyperspectral imagers are fast as compare to other systems. This segment is expected to register the fastest CAGR during the forecast period.
  • Others: Others include whiskbroom, tunable filter, and other technologies.
By Application
  • Surveillance: The majority of the hyperspectral imaging systems are used for defense and surveillance. Additionally, it can detect satellites, high-altitude reconnaissance aircraft, medium-altitude commercial aircraft, and drones. The market growth of the segment is majorly attributed to the increasing adoption of innovative technologies in the defense sector, along with the rising applications of unmanned aerial vehicles for surveillance purposes.
  • Medical Diagnostics: Medical diagnostics segment is anticipated to be the fastest-growing segment owing to the increasing applications of the hyperspectral imaging system in healthcare, such as the detection of the chemical composition of human tissues. Additionally, it has potential applications in non-invasive diagnosis.
  • Remote Sensing: Remote sensing is likely to hold significant market share in the global hyperspectral imaging system market. It is also known as imaging spectroscopy. It is used for the detection and identification of minerals, terrestrial vegetation, and human-made materials and backgrounds.
  • Machine Vision/Optical: Various hyperspectral imaging systems are used for machine vision/optical purposes.
By Region
  • Americas: Americas is estimated to be the largest regional market owing to the presence of prominent players in the major countries in America. Major market players such as Headwall Photonics, Inc., Resonon, Inc., Corning Incorporated, Applied Spectral Imaging, and Surface Optics Corporation have a significant presence in the Americas. The region is anticipated to dominate the global hyperspectral imaging system market owing to the well-established healthcare sector and rising healthcare spending in the region. According to the Committee for a Responsible Federal Budget, in 2017, the US has spent more than USD 3.5 trillion on healthcare-related expenses.
  • Europe: The European region holds the second largest share as there is increasing support from regulatory authorities to control cancer. Moreover, the rising expenses on defense and surge in demand for innovative and easy to use hyperspectral imaging systems have led to an increase in demand for hyperspectral imaging systems in the region.
  • Asia-Pacific: The Asia-Pacific region is anticipated to be the fastest-growing region in the global hyperspectral imaging system market. This region is witnessing a surge due to the increasing mining activities, and growing biotechnology and agriculture sector in developing countries such as India. According to the India Brand Equity Foundation, the Indian biotechnology sector is likely to reach around USD 12 billion in the year 2018. The growing biotechnology sector is likely to provide favorable conditions and anticipated to drive growth in the market.
  • Middle East & Africa: The smallest market due to limited healthcare infrastructure and limited exposure to innovative solutions.
Key Players
  • Headwall Photonics, Inc.
  • Specim, Spectral Imaging Ltd.
  • Norsk Elektro Optikk as (NEO)
  • Resonon, Inc.
  • Corning Incorporated
  • Telops
  • Applied Spectral Imaging
  • Bayspec, Inc.
  • Surface Optics Corporation
  • Chemimage Corporation
  • Cubert GmbH
  • Raytheon
  • Galileo Group, Inc.
  • Hypermed Imaging, Inc.
  • Inno-Spec
  • Camlin Group Ltd.
  • IMEC
  • XIMEA GmbH
  • OthersTop of Form
Bottom of Form

Posted by at No comments:

Global 4D Printing in Healthcare Market Growth Factors, Types And Application By Regional Analysis 2025

Market Overview
Global 4D Printing in Healthcare Market is expected to register a CAGR of 29.4% during the forecast period from 2019 to 2025 and expected to reach USD 30.4 Million by 2025.
In the past decade, there has been increasing use of 3D printing in the field of healthcare. The introduction of 4D printing and its shape-changing material property in the field of dentistry, implants, and prosthetics, among others will further enhance the 3D products used for these applications. The shape-changing property of the material used for 4D printing has been one of the major factors influencing the growth of the market.
Moreover, factors such as increasing research and development, rising investment by chemical companies. These chemical companies are keen on grabbing the opportunity for the development of smart materials in 4D printing, which in turn is directly enhancing the growth of the market.
Factors such as stringent regulatory policies for the approval of 4D printing medical devices market and limited skilled professionals have been major challenges for 4D printing in the healthcare market.  
Market Drivers
  • Increasing application of 4D printing in healthcare verticals such as dentistry, implants, and prosthetics.
    • The dental industry is one of the major applications of 4D printing. Clear aligners have been the most manufactured products via 3D printing in the dental industry.
    • Align technology, the leader in global clear aligners market, accounts for about 80% of the market. The company uses 3D Systems to produce over 1.6 million custom aligners per week.
    • Clear aligners can further be enhanced using 4D printing, as these products require shape altering properties according to the changing structure of the teeth on a weekly basis.
    • 4D printers are also used to manufacture various dental implants, including dental implants, dentures, crowns, & bridges, among others.
    • Increasing prevalence of dental diseases is further influencing the growth of the market. According to the MRFR research study in 2018, it was estimated that oral diseases affected more than 3.7 billion individuals that are around half of the world’s population.
  • Rising research and development
    • A research team from the US in March 2019, invented a new bio-ink that allows to print catalytically active live cells into several self-sustaining 3D geometries. These properties include tunable cell densities, fine filament thickness, and high catalytic productivity.
  • Growing investment by chemical companies
    • Various companies such as BASF Venture Capital GmbH and Evonik Venture Capital have invested in Chinese 3D printing companies
Market Challenges
  • Stringent regulatory policies for the approval of 4D printing medical devices
  • Limited skilled professionals
Segmentation
By Component
  • Software & Services: Software and services accounted for the major market share in 2018. 3D printers have already been installed in numerous healthcare facilities across the globe. However, these machines would require updated software and also various services for the manufacturing of 4D products.
  • Smart Material: Smart Material segment is expected to grow at the fastest growth rate due to continuous advancements for the materials in 4D printing. Investment by chemical companies for the development of smart material is further influencing the market growth.
By Technology
  • Fused Deposition Modeling: Accounted for the largest market share due to its wide choice of raw materials and cost-effective process
  • Direct Inkjet Cure: Expected to grow at the fastest growth rate majorly due to its dimensional accuracy, multi-material, and full-color printing properties
By Application
  • Dental: accounted for the largest market share owing to the use of 4D printing for manufacturing of wide dental products including clear aligners, implants, and dentures among others
  • Prosthetics: Expected to grow at the fastest growth rate due to increasing number of prosthetic procedures, accidental injuries, and sports injuries among others
By End-User
  • Hospitals & Surgical Centers: Accounted for the leading market share owing to the increasing number of hospital & surgical centers. According to a study published by the American Hospital Association, there were 5,534 registered hospitals in the US in 2017.
  • Dental Clinics & Laboratories (Offices): Use of 4D printing in dental clinics & laboratories, brings less complexity to existing procedures. Dental laboratories use 4D printing technologies that allow them to increase competitiveness and production, thus driving the growth of this segment.
By Region
  • Americas: The Americas spearheaded the market in 2018 and is likely to continue to command during the assessment period. This is attributed to the existence of a large number of medical device companies, increasing research and development, and the presence of a large number of noticeable players engaged in manufacturing of 4D printing devices and software
  • Europe: Reported for the second-largest share owing to increasing utilization of 3D & 4D printing in the field of healthcare. According to a study conducted in 2018, it was found that 65% of healthcare providers are implementing new printing technologies for medical products using custom made materials
  • Asia-Pacific: The highest growth rate is attributed to the growing investment by government bodies and private & public companies. For instance, in November 2018, BASF Venture Capital GmbH invested in Chinese 3D printing company Prismlab.
Key Development
  • In January 2019, Dentsply Sirona and Carbon announced a strategic collaboration to revolutionize digital denture materials. This strategic collaboration was announced to deliver denture materials for carbon digital 3D printing production solutions.
Key Players
  • Stratasys Ltd (US)
  • 3D Systems, Inc (US)
  • EnvisionTEC (Germany)
  • Poietis
  • (France) 
  • Organovo Holdings Inc. (US)
  • Materialise NV (Belgium)
  • Dassault Systèmes (France) Top of Form
Bottom of Form


Posted by at No comments:

Meningococcal Vaccines Market 2019 – Leading Manufactures, Regions, Drivers, Analysis And Forecasts Till 2025

Meningococcal Vaccines Market has a demand for USD 172 Million doses in 2019. Further, the global estimated supply in 2019 is expected to be 203 Million doses.
Market Synopsis
Meningococcal meningitis is a bacterial infection caused by Neisseria meningitides. Disease incidence is high in West and Central Africa, where historically, serogroup A has been the most important cause of disease. More recently, meningitis outbreaks have gradually been associated with serogroup C, and to a lesser extent, serogroup W.
The meningococcal vaccines market is complex and diverse, with regional variations in serogroup distribution with substantial use outside routine immunization. The vaccine has approximately 29 marketed products targeting various combinations of the six serogroups (A, B, C, W, X, Y).
Market Influencer
Without an increase in production, the existing supply of conjugate MenACWY will be inadequate to meet the demand generated by the rising incidence of serogroups C and W, and the low availability of polysaccharide vaccines. Further, several multivalent, conjugate vaccines by Chinese and Indian manufacturers are in the pipeline, and, if prequalified they will be registered for use in many geographies. Moreover, if they are made available at acceptable prices it could increase global demand in Meningococcal Vaccines Market.
Market Drivers
  • Rise in prevalence of the meningococcal disease
    • According to a document published by the U.S. Department of Health & Human Services, in 2017, there were approximately 350 cases of meningococcal disease reported. The disease has an incidence rate of 0.11 cases per 100,000 people in the United States. Any population group can be affected by the disease, with maximum prevalence in children younger than one-year-old and a second peak in adolescence. Adolescents and young adults, ranging from 16 to 23 years old, have the highest rates of meningococcal disease.
    • Further, increasing incidence of meningococcal disease in West and Central Africa regions is expected to drive the demand in the African region
  • Booming mortality of the meningococcal disease is leading to increasing demand for the vaccines
    • Approximately 10 to 15 in 100 people affected with meningococcal disease will face mortality. Further, up to 1 in 5 survivors will have long-term disabilities, such as loss of limb, deafness, and damage to the nervous system brain among others
  • Escalating positive results with the vaccines to boost the demand in the market
  • Growing research and development activities by prominent players in the industry
Market Restraints
  • Withdrawn production of polysaccharide vaccines has resulted in reduced country access, particularly for MICs in various regions. For example, Sanofi Pasteur, manufacturer of Menomune, declared in 2017 that the company is discontinuing the production of the vaccine. With the production of Menomune at hold, there were no polysaccharide vaccines approved for use in the United States

Meningococcal Vaccines Market Segmentation

By treatment, the market is segmented into Meningococcal Conjugate Vaccine, Polysaccharide, Subcapsular Vaccine.
Meningococcal A conjugate vaccine is significantly used in mass campaigns across affected regions like Africa. Since 2010, the vaccine has significantly decreased meningococcal disease incidence in the region. However, the demand for meningococcal A conjugate in the country remains uncertain given that national immunization program adoptions are based on the timing of Gavi funding decisions, the country’s readiness, and competing for vaccine introduction priorities.
In the polysaccharide segment, products such as MenACWY vaccines are in high demand. MenACWY vaccine is the most desirable combination, given its broader serotype coverage. MenACWY specifically has nine products that are available across polysaccharide and conjugate product segments, but conjugate products are suggested for use in routine immunization activities.
Moreover, the demand and supply of Subcap MenB vaccines is restricted to HICs and influenced by their acceptance into NIPs. Improved uptake of MenB vaccines is expected in the coming years but will likely be moderate and limited to high-income markets given the high price and competing interest of introducing MenACWY conjugate.
By end-user, the market is segmented into Hospital & Clinical, Research Laboratories, and Academic Institutes
Hospitals and clinics control the global market for meningococcal vaccines. The high growth of hospitals and clinics segment is attributed to the increasing application of vaccines in these healthcare facilities in conjunction with the growing prevalence and incidence of the meningococcal disease.
Moreover, research laboratories and academic institutes take up the second-largest share due to the boost in research and development in the market.
By region, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
In the global market, China is expected to have the largest market share, which accounts for approximately 35% of the global demand. This is primarily due to polysaccharide products, which currently comprise 84% of China’s demand. Chinese suppliers presently focus only on meeting the demand of the domestic market, but some of the manufacturers have indicated interest in the global market as well. The dynamic product pipeline with several multivalent conjugate products in development may trigger changes in the future supply mix of the Chinese market. Moreover, in China, non-routine use (excluding campaigns) accounts for an estimated 9 million doses in 2019, which may help to sustain the huge market share in the forecast period.
UNICEF foresees all 26 African countries in the meningitis belt, which have completed mass campaigns in 2016. In 2015, seven countries in the region were introduced with meningococcal A conjugate vaccine through their mass campaigns and targeted a population of 233 million. Further, during 2016-2018, UNICEF introduced meningococcal A conjugate vaccine in 26 countries. Ghana was the first country to be introduced with the vaccine into its RI schedule in 2016. Also, four other countries including Mali, Niger, Nigeria, and Sudan introduced the vaccine into RI programs in 2016.
Key Developments in the Global Meningococcal Vaccines Market
  • In 2018, Pfizer granted FDA Breakthrough Therapy designation for Trumenba (Meningococcal Group B Vaccine). This vaccine plays a major role in the prevention of invasive meningococcal B disease in children aged 1 to 9 years
  • In 2018, GSK’s meningitis B vaccine Bexsero received Breakthrough Therapy designation from the US FDA for prevention of Invasive Meningococcal Disease for children 2-10 years of age
  • In 2015, Novartis Bexsero vaccine was approved by the FDA for the prevention of meningitis B. This vaccine is used as active immunization to prevent invasive meningococcal disease caused by serogroup B
Key Players
  • Baxter international
  • Pfizer Inc.
  • Sanofi S.A.
  • Novartis Pharmaceuticals Inc.
  • JN-International Medical Corporation
  • Serum Institute of India Ltd.
  • GlaxoSmithKline
  • BIO-MED
  • Others
Bottom of Form
 Bottom of Form
Bottom of Form
Bottom of Form
Browse more Details of the Report @
Posted by at No comments:

Global Cell Counting Market Outlook, Key Financials, Segmental Revenue And Geographical Revenue Till 2025

Market Forecast

Cell Counting Market is expected to cross USD 12.57 Billion by 2025 at a CAGR of 5.8%.
Market Synopsis
Cell counting is one of the methods for counting cells in life sciences, including medical diagnosis and treatment. The companies operating in this market acquire both organic and inorganic growth strategies to maintain and develop their positions in the market. The increasing funding for stem cell-based research supports the growth of the market.
Market Influencer
Increasing public-private investments and funding in stem cell-based research impact the growth of the cell counting industry positively.
Market Drivers
  • The increasing use of stem cells in various therapeutics is promoting government and private institutes to raise the funding for more development in this area. For instance, in March 2019, the governing Board of the California Institute for Regenerative Medicine (CIRM) funded USD 3.9 million to Ankasa Regenerative Therapeutics to develop the treatment for spinal degeneration which can cause chronic, progressive back pain.
  • The growth of the market is driven by the increasing number of product launches in the global cell counting devices market. Recently, in January 2019 the DeNovix Inc. launched CellDrop Cell Counting without Slides.
  • The cell counting market growth is supported by Increased R&D expenditure in the healthcare industry.
  • Increasing number of stem cell organizations globally support the growth of the market.
  • Rising incidence & prevalence of cancer will support the growth of the market.
Market Restraints
  • The high cost of devices and product recalls are likely to hamper the growth of the cell counting market during the forecast period. Recently in May 2019, Beckman Coulter Inc. recalled DxH800 and DxH600 and DxH 900 hematology analyzers due to risk of inaccurate results.
Cell Counting Market Segmentation
By Product
  • Consumables: The consumables segment includes reagents, assay kits, microplates, and others. The instruments are further segmented into reagents, assay kits, microplates, and others. This segment holds the largest share in the cell counting market due to repeating purchase of consumable products.
  • Instruments: Instruments are used in cell counting methods. The instruments are further segmented into spectrophotometers, flow cytometers, hematology analyzers, and cell counters. Increasing number of product launches will support the growth of the market. Recently in April 2019, the Nexcelom Bioscience LLC launched Cellaca MX automated cell counter.
By Application
  • Research Application: Cell counting is used for research applications for discovering new medicines. Cell counting has the main application in stem cell research to develop advanced therapy for various diseases. This segment holds the largest share in the cell counting market.
  • Clinical & Diagnostic Applications: Cell counting has a significant role in clinical and diagnosis applications. It is used for diagnosis of various kinds of blood disorders, including infection, anemia, and leukemia.
  • Others: Others include industrial and other commercial applications.
By End-User
  • Pharmaceutical & Biotechnology Companies: The largest segment, pharmaceutical, and biotechnology companies, primarily use cell counting for research purposes. In 2018, the pharmaceutical and biotechnology companies segment held the largest share of the market.
  • Hospitals: Hospitals used cell counting products for the diagnosis of various kinds of diseases such as blood disorders and malaria, among others.
  • Research Institutes: These re involved in specific research activities to develop new and advance treatment for various diseases. Stem cell research institutes are major consumers for cell counting products.
  • Others: These include academic institutes, among others.
By Region
  • Americas: The Americas dominates the global cell counting market owing to an increase in the incidence of cancer, the presence of well-established pharmaceutical and biotechnology industry, availability of technologically advanced products, and significant support from the government in the form of funds and grants.
  • Europe: The key factors driving the market growth are the growing research and development funding and support by government bodies for the healthcare sector, the presence of major manufacturers, and growing healthcare expenditure, among others.
  • Asia-Pacific: Asia-Pacific is the fastest-growing region for the cell counting market. This is due to developing healthcare infrastructure and rising drug development researchers.
  • Middle East & Africa: It is projected to account for the least share of the global market due to low per capita disposable incomes in the region and limited development of healthcare facilities.
Key Players
  • Thermo Fisher Scientific (US)
  • Merck KGaA (Germany)
  • Danaher Corporation (US)
  • Bio-Rad Laboratories, Inc. (US)
  • Logos Biosystems, Inc. (South Korea)
  • Olympus Corporation (Japan)
  • Agilent Technologies, Inc. (US)
  • PerkinElmer, Inc. (US)
  • Sysmex Corporation (Japan)
  • Abbott Laboratories (US)
Posted by at No comments:

Medical Drones Market Forecasts By Industry Drivers, Regions Till 2025

Market Forecast
Medical Drones’ Market is expected to worth USD 398 Million by 2025 and is anticipated to register a CAGR of 24.4% during the forecast period (2019 to2025).
Market Synopsis
Medical drones help in the transport of medical supplies such as vaccines, medications, and medical aids. These drones are deployed in remote or inaccessible areas for the rapid & secure distribution of medical supplies and the war-torn regions from medical facilities. Rising public acceptance of medical drone is also driving the growth in medical drones market demand.
Medical Drones Market , In recent years, has been seeking the attention of healthcare providers and governments to offer better healthcare services to remote locations. These drones help in on-time delivery of vaccines, medication, blood, and supplies to the origin and thereby reduce the outbreaks of life-threatening infectious diseases.
How can this technology help in improving safety and care delivery?
  • Bedside medication delivery
  • Effective treatment from the distance
  • Easy reach to an isolated place
  • Pre-treatment facility till the time emergency service arrives at takeover
Most of the key players in the market are focusing on developing medical drones to deliver medical supplies to far distances. For instance, in 2016, a Nevada based start-up Flirtey delivered medical test materials and supplies to and from an offshore vessel. This was the first successful ship to shore delivery in the U.S.
Market Influencer
Increasing investments by key players in R&D is the key factor driving the growth of the Global Medical Drones’ Market.
Market Drivers
  • Rising participation of Governments in various countries: Active involvement of local governments towards the deployment of drone service to remote and isolated areas is boosting the growth of the market. For instance, in 2018, the government of Ghana has signed an agreement with Zipline (US) for the deployment of drones throughout the country to provide medical supplies to untapped regions
  • Increasing application of drone for the supply of medical products such as blood, pharmaceuticals/drugs, and vaccines are anticipated to propel the market growth during the forecast period
  • Technological advancements to improving the accuracy of medical drones during emergency cases backed by R&D activities by key players
Market Restraints
  • Medical drones. Medical drones are not allowed to fly without the permission of the government. Thus, product approval laws are expected to restrict the growth of the medical drone’s market during the forecast period.
Segmentation
By Application
  • Blood Transfer: Rising incidence of severe bleeding deaths is boosting the demand for medical drones. The blood transfer segment is anticipated to show a growth rate of ~24% during the analysis period. According to the MRFR analysis, each year, around 60,000 Americans die from blood loss or hemorrhaging. Moreover, around 2 million people die across the globe.
  • Pharmaceutical/Drugs Transfer: The increasing focus of key medical drones vendors towards the development of drones for medication delivery is boosting the growth of this segment.
  • Vaccines Transfer: This segment is mainly on the drones that are associated with the delivery of the vaccine.
By End-User
  • Emergency Medical Services: This segment held the largest market share in 2018, owing to continues advancements in technology. For instance, in 2019, an automated drone’s delivery company Zipline (US), has planned for the expansion of a medical drone network into Ghana for emergency services.
  • Blood Banks: Owing to poor road conditions, transporting blood in underdeveloped countries is a huge task. Medical drones carry blood, plasma, and platelets from blood banks to remote hospitals and clinics.
By Region
  • Americas: The Americas held the largest regional market in 2018, owing to rising technology advancement. Moreover, the governments in this region are also promoting the acceptance of medical drones, as a result, players are aggressively working to develop advanced drones. In October 2019, United Parcel Services (US) received an authority from the Federal Aviation Administration to deliver medical packages at hospitals across the country.
  • Europe: The European market is expected to be the second-largest market in 2025. The market growth in this region can be attributed to government funding and support to the healthcare sector, coupled with increasing research and development.
  • Asia-Pacific: Asia-Pacific is the fastest-growing region for the medical drones market owing to the improving healthcare infrastructure, rising investments in healthcare, and expansions by market players in the region. Also, countries such as India and China are expected to be the fastest-growing in the region due to the focus of governments towards the adoption of new technologies and faster adoption of best treatment options from developed countries.
  • Middle East & Africa: It is projected to account for the least share of the global market due to an underdeveloped healthcare sector.
Key Players
  • DJI (China)
  • DHL (Germany)
  • Embention (Spain)
  • Flirtey (US)
  • Matternet (US)
  • Vayu (US)
  • Zipline (US)
  • EHang (China)
  • TUDelft (Netherlands)
Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/medical-drones-market-8596 Bottom of Form
Posted by at No comments:

Thalassemia Treatment Market Shares Analysis, Key Development Strategies And Forecasts Till 2025

Market Forecast
Thalassemia Treatment Market is expected to cross USD 3763 Million by 2025 at a CAGR of 10.4%.
Thalassemia, specifically the Beta- thalassemia disorder, is majorly caused by the mutation in the Hemoglobin Subunit Beta (HBB) gene. For instance, at least 5.2% of the world population and over 7% of pregnant women have a genetic mutation.
Market Synopsis
Thalassemia Treatment Market analysis asserts that, Thalassemia is an inherited blood disorder wherein the body makes an inadequate amount of hemoglobin. Hemoglobin disorders were initially prevalent in 60% of 229 countries, that potentially affected 75% of births, but are now sufficiently common in 71% of countries amongst 89% of births.
Market Influencers
Major companies are concentrating on mergers and acquisitions, new product developments, approvals, and regional expansions. For instance, in September 2019, Bluebird Bio, Inc. (US) has approved the first gene therapy for Beta-thalassemia. This gene therapy eliminates the need for blood transfusions in patients with β-thalassemia. Thus, major manufacturers are focusing on approvals in thalassemia treatment, which ultimately drives the growth of the market.
Market Drivers
  • The rising incidence of thalassemia is expected to drive the growth of the market. Patients with insufficient hemoglobin suffer from thalassemia. For instance, thalassemia affects approximately 4.4 of every 10,000 live births throughout the world.
  • Increasing pipeline drugs in thalassemia is expected to drive the growth of the market. There are approximately 15 pipeline products under clinical trials for the treatment of thalassemia. For instance, in December 2016, Kiadis Pharma announced initiation of Phase I/II clinical trial with ATIR201 for thalassemia.
  • A rise in awareness regarding available treatment options for the treatment of thalassemia is expected to drive the growth of the market.
  • The rise in demand for improved curative gene therapy is expected to drive the growth of the market.
Market Restraints
  • Stringent regulatory policies
  • High treatment costs
Segmentation
By Type
  • Alpha-thalassemia: Fastest growing segment. It is one of the most common autosomal recessive disorders. There is an increased incidence of the alpha-globin disorders in the US and other Western nations which eventually drives the growth of the thalassemia treatment market. However, about 5% of the world’s population is affected by alpha-thalassemia.
  • Beta Thalassemia: It is caused by reduced or no production of beta-globin subunits. About 1.5% of the global population is affected by Beta-thalassemia.
By Treatment
  • Blood Transfusions: The largest growing segment owing to the low risks involved due to careful blood screening. This treatment gives strong red blood cells along with normal hemoglobin. About 56,000 population have major thalassemia, wherein, at least 30,000 need regular blood transfusions. Thus, rising demand for blood transfusions is expected to drive the growth of the market.
  • Iron Chelation Therapy: This includes removing excess iron from the bloodstream. Iron chelator drugs such as desferrioxamine, deferiprone, and deferasirox are majorly used in this treatment.
  • Folic Acid Supplements: Folic acid is vitamin B that helps build strong red blood cells. These supplements are majorly consumed during and after pregnancy. However, 4% had started consuming after becoming pregnant. Thus, the increased use of folic acid is expected to drive the growth of this segment.
  • Gene therapy: Scientists are investigating genetic techniques to treat thalassemia. Gene therapy named Zynteglo was first launched by Bluebird Bio, Inc. (US) in September 2019.
  • Bone Marrow transplants: These transplants are not done very often as significant risks are involved but can be tried if no bone marrow matched donor is available. However, the patient will not need further blood transfusions if this transplantation is done. As a result, it would drive the market growth in this segment.
By End-User
  • Hospitals & Clinics: Holds the largest market share owing to the increase in the number of hospital admissions for the treatment of thalassemia. Moreover, increasing occurrence of thalassemia is also expected to drive this segment.
  • Diagnostic laboratories: This segment holds significant market share owing to the increasing awareness regarding thalassemia treatment.
  • Others: This segment includes research laboratories, educational institutes, among others.
By Region
  • Americas: The largest growing regional market owing to rising awareness about thalassemia and increasing government efforts to support gene therapy. However, Beta-thalassemia disorder is relatively rare in the US.
  • Europe: The introduction of gene therapy for the treatment of thalassemia is expected to boost the growth of market. For instance, in September 2019, Bluebird Bio, Inc. (US) has obtained approval for gene therapy that would remove the need for blood transfusions for people with blood disorder beta-thalassemia.
  • Asia-Pacific: The fastest-growing regional market in thalassemia treatment. Increasing investment in healthcare infrastructure is expected to drive the growth of the market in this region.
  • Middle East & Africa: Increasing adoption rate of blood transfusion treatment in countries such as Turkey and GCC would drive the demand for thalassemia treatment in this region.
Key Players
  • Novartis AG (Switzerland)
  • Bluebird Bio, Inc. (US)
  • Kiadis Pharma (Netherlands)
  • CELGENE CORPORATION (US)
  • Sangamo Therapeutics (US)
  • Acceleron Pharma, Inc. (US)
  • Gamida Cell (Israel)
Posted by at No comments:
Subscribe to: Posts (Atom)